5-fluorouracil (5-FU) treatment resulted in a 1.6% overall incidence of cardiopathy, with a significantly higher risk in patients with a history of previous cardiopathy (4.5% vs 1.1%).
Observational (n=1,083)
What is the incidence of cardiotoxicity in patients receiving 5-fluorouracil chemotherapy for neoplasms?
5-fluorouracil chemotherapy is associated with a 1.6% incidence of cardiotoxicity, which is significantly higher (4.5%) in patients with pre-existing cardiac disease.
The possible onset of cardiotoxic manifestations during chemotherapy with 5-fluorouracil (5-FU) was evaluated in 1083 patients treated with the drug for various kinds of neoplasm. We recognized 17 cases of 5-FU cardiopathy (usually anginous crises but also myocardial infarction). The comprehensive incidence was 1.6%, with a significantly greater risk (4.5% vs 1.1%) for patients with a positive anamnesis of previous cardiopathy. On the contrary, age and combination with other antiblastic drugs had no affect on the appearance of cardiopathy. We conclude that 5-FU cardiopathy, although rare, has to be taken into account in oncologic practice, chiefly in those patients already affected with cardiac diseases.
Labianca et al. (Wed,) conducted a observational in Neoplasm (n=1,083). 5-fluorouracil (5-FU) was evaluated on 5-FU cardiopathy (anginous crises or myocardial infarction). 5-fluorouracil (5-FU) treatment resulted in a 1.6% overall incidence of cardiopathy, with a significantly higher risk in patients with a history of previous cardiopathy (4.5% vs 1.1%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: